Home » Stocks » Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NBIX)

Stock Price: $114.39 USD -0.35 (-0.31%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 10.67B
Revenue (ttm) 1.01B
Net Income (ttm) 204.79M
Shares Out 93.25M
EPS (ttm) 2.08
PE Ratio 55.00
Forward PE 60.61
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $114.39
Previous Close $114.74
Change ($) -0.35
Change (%) -0.31%
Day's Open 114.06
Day's Range 113.87 - 115.25
Day's Volume 332,778
52-Week Range 72.14 - 136.27

More Stats

Market Cap 10.67B
Enterprise Value 10.22B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 93.25M
Float 92.02M
EPS (basic) 2.22
EPS (diluted) 2.08
FCF / Share 3.71
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.82%
FCF Yield 3.24%
Payout Ratio n/a
Shares Short 4.82M
Short Ratio 7.88
Short % of Float 6.12%
Beta 1.30
PE Ratio 55.00
Forward PE 60.61
P/FCF Ratio 30.91
PS Ratio 10.61
PB Ratio 12.68
Revenue 1.01B
Operating Income 274.32M
Net Income 204.79M
Free Cash Flow 345.13M
Net Cash 447.70M
Net Cash / Share 4.80
Gross Margin 57.73%
Operating Margin 27.28%
Profit Margin 20.40%
FCF Margin 34.32%
ROA 17.26%
ROE 31.15%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (24)

Buy 15
Overweight 1
Hold 8
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$140.29*
(22.64% upside)
Low
120
Current: $114.39
High
161
Target: 140.29
*Average 12-month price target from 21 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue78845116215.0019.77-2.9253.1477.4133.50
Revenue Growth74.65%179.19%977.51%-24.12%---94.51%-31.36%131.08%-
Gross Profit78144616015.0019.77-2.9253.1477.4133.50
Operating Income72.2836.90-131-147-94.20-64.41-49.681.4533.92-13.72
Net Income37.0121.11-143-141-88.93-60.54-46.095.0337.57-7.97
Shares Outstanding91.6390.2488.0986.7184.5074.5866.9965.6255.1852.82
Earnings Per Share0.390.22-1.62-1.63-1.05-0.81-0.690.080.67-0.15
EPS Growth77.27%-------88.06%--
Operating Cash Flow152101-94.33-106-38.00-47.14-29.61-35.29-0.7049.94
Capital Expenditures-14.74-24.78-6.93-4.10-1.93-1.57-0.51-0.94-0.510.02
Free Cash Flow13776.59-101-110-39.92-48.71-30.11-36.23-1.2049.96
Cash & Equivalents674656520312384199150177133133
Total Debt496388370-------
Net Cash / Debt178268151312384199150177133133
Assets1,306993818365475243155196138144
Liabilities66951244550.2150.3334.3334.2741.6178.29125
Book Value63748137231542420912015460.0819.35
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Neurocrine Biosciences, Inc.
Country United States
Employees 780
CEO Kevin Charles Gorman

Stock Information

Ticker Symbol NBIX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NBIX
IPO Date May 23, 1996

Description

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL ? Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.